Free radicals in anticancer drug pharmacology

doi:10.1016/0009-2797(89)90117-8

Chemico-Biological Interactions

Volume 69, Issue 4, 1989, Pages 293-317

https://doi.org/10.1016/0009-2797(89)90117-8 Get rights and content

Abstract

This review examines the formation of free radical intermediates from a number of clinically active antitumor agents including quinone-containing antibiotics and etoposide. An attempt is also made to relate the formation of these reactive intermediates to biochemical and pharmacological basis for tumor cell kill and resistance. The formation of these intermediates in some tumor cells has been detected by both direct ESR and spin-trapping technique. The detection of free radicals in biological systems, however, depends upon cellular bioenvironments, e.g. reducing conditions, and the presence and/or absence of activation and detoxification mechanisms. Evidence shows that certain antitumor drugs generate free radicals in vitro and in vivo and that these reactive species kill tumor cells by causing damage to DNA, membranes or enzymes.

References (115)

B. Kalyanaraman et al.
Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs
Biochim. Biophys. Acta
(1980)
B. Kalyanaraman et al.
An electron resonance study of the reduction of peroxides by anthracycline semiquinones
Biochim. Biophys. Acta
(1984)
T. Komiyama et al.
Generation of hydroxyl radical by anticancer drugs carbazilquinone, mitomycin C, aclacinomycin A, and Adriamycin in the presence of NADPH-cytochrome C reductase
Biochem. Pharmacol.
(1982)
B.K. Sinha et al.
Binding mode of chemically activated semiquinone free radicals from quinone anticancer agents to DNA
Chem.-Biol. Interact.
(1979)
B.K. Sinha et al.
Free radical metabolism of VP-16 and inhibition of anthracycline-induced lipid peroxidation
Biochem. Pharmacol.
(1983)
N. Haim et al.
Peroxidative free radical formation and O-demethylation of etoposide (VP-16) and teniposide (VM-26)
Biochem. Biophys. Res. Commun.
(1986)
B.K. Sinha
Metabolism activation of procarbazine: evidence for carbon-centered free radical intermediates
Biochem. Pharmacol.
(1984)
E. Calendi et al.
On physico-chemical interactions between daunomycin and nucleic acids
Biochim. Biophys. Acta
(1965)
A. DiMarco et al.
Interactions of some daunomycin derivatives with deoxyribonucleic acid and their biological activity
Biochem. Pharmacol.
(1971)
B.K. Sinha et al.
Role of one-electron and two-electron reduction products of Adriamycin and daunomycin in DNA binding
Biochem. Pharmacol.
(1981)

B.K. Sinha et al.

Binding of Adriamycin to cellular macromolecules in vivo

Biochem. Pharmacol.

(1980)

E. Goormaghtigh et al.

Evidence of a specific complex between Adriamycin and negatively charged phospholipids

Biochim. Biophys. Acta

(1980)

M. Potmesil et al.

Two mechanisms of Adriamycin-DNA interactions in L1210 cells

Biochem. Pharmacol.

(1984)

J.H. Doroshow

Prevention of doxorubin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents

Biochem. Biophys. Res. Commun.

(1986)

B.K. Sinha et al.

Adriamycin-stimulated hydroxyl radical formation in human tumor cells

Biochem. Pharmacol.

(1987)

G. Batist et al.

Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells

J. Biol. Chem.

(1986)

W.S. Thayer

Serum lipid peroxides in rats treated chronically with Adriamycin

Biochem. Pharmacol.

(1984)

R.A. Floyd et al.

Use of salicylate with high pressure liquid chromatography and electrochemical detection (LCED) as a sensitive measure of hydroxyl radicals in Adriamycin treated rats

J. Free-Rad. Biol. Med.

(1986)

H. Nakano et al.

Inhibition by the protein ceruloplasmin of lipid peroxidation stimulated by an Fe³⁺-ADP-Adriamycin complex

FEBS Lett.

(1984)

L. Gianni et al.

Characterization of the cycle of iron-mediated electron transfer from Adriamycin to molecular oxygen

J. Biol. Chem.

(1985)

L. Gianni et al.

Characterization of the cycle of iron-mediated electron transfer from Adriamycin to molecular oxygen

J. Biol. Chem.

(1985)

J.R.F. Muindi et al.

Hydroxyl radical production and DNA damage by anthracycline-iron complex

FEBS Lett.

(1984)

C.E. Myers et al.

5-Iminodaunomycin: an anthracycline with unique properties

J. Biol. Chem.

(1987)

E.J.F. Demant et al.

Binding of transferrin-iron by Adriamycin at acidic pH

FEBS Lett.

(1986)

M. Gosalvez et al.

Quelamycin, a new derivative of Adriamycin with several possible therapeutic advantages

Eur. J. Cancer

(1978)

P.L. Gutierrez et al.

Free radicals in quinone-containing antitumor agents: the nature of the diaziquone [3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone] free radicals

Biochim. Biophys. Acta

(1983)

P.L. Gutierrez et al.

Cellular activation of diaziquinone [3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone] to its free radical species

Biochem. Pharmacol.

(1985)

M.M. Mossoba et al.

Diaziquonone as a potential agent for photoirradiation therapy: formation of the semiquinone and hydroxyl radicals by visible light

Biochem. Biophys. Res. Commun.

(1985)

B.K. Sinha et al.

Irreversible binding of etoposide (VP-16-213) to deoxyribonucleic acid and proteins

Biochem. Pharmacol.

(1984)

B.K. Sinha et al.

Microsomal interactions and inhibition of lipid peroxidation by etoposide (VP-16-213): implications for mode action

Biochem. Pharmacol.

(1985)

N. Haim et al.

In vitro metabolism of etoposide (VP-16-213) by liver microsomes and irreversible binding of reactive intermediates to microsomal proteins

Biochem. Pharmacol.

(1987)

D. Ross et al.

The reaction and subsequent fate of glutathionyl radical in biological systems

J. Biol. Chem.

(1985)

A.G. Katki et al.

Interactions of the antitumor drug, etoposide with reduced thiols in vitro and in vivo

Chem.-Biol. Interact.

(1987)

B.K. Sinha et al.

Iron-dependent hydroxyl radical formation and DNA damage from a novel metabolite of the clinically active antitumor drug VP-16

FEBS Lett.

(1988)

R.J. Weinkam et al.

Metabolic activation of procarbazine

Life Sci.

(1978)

F.N. Dost et al.

Methane formation in vivo from N-isopropyl-(2-methylhydrazino)-p-toluamide hydrochloride, a tumor-inhibiting methylhydrazine derivative

Biochem. Pharmacol.

(1967)

R.P. Mason

Free radical intermediates in the metabolism of toxic chemicals

J.W. Lown

Molecular mechanism of action of anticancer agents involving free radical intermediates

Adv. Free-Rad. Biol. Med.

(1985)

N.R. Bachur et al.

A general mechanism for microsomal activation of quinone anticancer agents

Cancer Res.

(1978)

E.G. Mimnaugh et al.

Adriamycin-enhanced lipid peroxidation in isolated rat nuclei

Cancer Res.

(1985)

C.A. Pritsos et al.

Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics

Cancer Res.

(1986)

S.R. Keys et al.

Role of NADPH-cytochrome c reductase and DT-diaphorase in the bioactivation of mitomycin C

Cancer Res.

(1984)

S. Pan et al.

Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase

J. Biol. Chem.

(1985)

J.W. Lown et al.

Further studies on the generation of reactive oxygen species from activated anthracyclines and the relationship to cytotoxic action and cardiotoxic effects

Biochem. Pharmacol.

(1982)

M. Tomaz et al.

The mode of interactions of mitomycin C with deoxyribonucleic acids and other polynucleotides in vitro

Biochemistry

(1974)

Y. Sugiura et al.

Formation of superoxide and hdyroxyl radicals in iron (II)-bleomycin-oxygen systems: electron spin resonance detection by spin trapping

J. Antiobiot. (Tokyo)

(1978)

E.A. Sausville et al.

Effects of chelating agents and metal ions on the degradation of DNA by bleomycin

Biochemistry

(1978)

H. Kuramochi et al.

An active intermediate formed in the reaction of bleomycin-Fe (II) complex with oxygen

J. Antibiot. (Tokyo)

(1981)

B.K. Sinha

Binding specificity of activated anthracycline anticancer agents to nucleic acids

Chem.-Biol. Interact.

(1980)

B.K. Sinha et al.

Enzymatic activation and binding off Adriamycin to nuclear DNA

Cancer Res.

(1984)

Cited by (114)

Natural compounds and anticancer effects: The whole is greater than the sum of its parts
2020, Functional Foods in Cancer Prevention and Therapy
Natural compounds are reemerging as intriguing reservoirs of biologically active compounds. In fact, a majority of the world's population relies on traditional medicine for health care.
Historically, natural products for anticancer studies have led to important accomplishments. More than 60% of the clinical use of antitumor drugs comes from natural products, including marine organisms, plants, and bacteria while more than 3000 species of plants can be utilized to fight neoplasms.
In view of emerging evidence, many studies are now directed to characterize the interactions and efficacy of natural compounds and classic chemotherapy drug combinations against several cancer types.
Promising results are giving renewed hope for the use of natural compounds and chemotherapeutics as partners in tumor therapy.
Natural products as multidrug resistance modulators in cancer
2019, European Journal of Medicinal Chemistry
Citation Excerpt :
Beside antiapoptotic defense one more system that can hamper the activity of anticancer drugs is the antioxidant defense system, as most of these drugs induce free radical generation and this oxidative stress results in damage on the level of proteins, nucleic acids, and cell membranes, but some pre-existing systems in the body which normally protects the cells against these free radicals also protects the cancerous cells from the damage by these radicals. These systems include the cytochromes, superoxide dismutase, catalase, glutathione peroxidase, and antioxidants [4,14–18]. As evident from the name the pump resistance is the one which depends on membrane-bound active efflux pumps.
Cancer is a prominent cause of death globally. Currently, many drugs that are in clinical practice are having a high prevalence of side effect and multidrug resistance. Risk of tumors acquiring resistance to chemotherapy (multidrug resistance) remains a significant hurdle to the successful treatment of various types of cancer. Membrane-embedded drug transporters, generally overexpressed in cancer, are the leading cause among multiple mechanisms of multidrug resistance (MDR). P-glycoprotein (P-gp) also MDR1/ABCB1, multidrug resistance associated protein 1 (MRP1/ABCC1), MRP2 and breast cancer resistance protein (BCRP/ABCG2) are considered to be a prime factor for induction of MDR. To date, several chemical substances have been tested in a number of clinical trials for their MDR modulatory activity which are not having devoid of any side effects that necessitates to find newer and safer way to tackle the current problem of multidrug resistance in cancer. The present study systematically discusses the various classes of natural products i.e flavonoids, alkaloids, terpenoids, coumarins (from plants, marine, and microorganisms) as potential MDR modulators and/or as a source of promising lead compounds. Recently a bisbenzyl isoquinoline alkaloid namely tetrandrine, isolated from Chinese herb Stephania tetrandra (Han-Fang-Chi) is in clinical trials for its MDR reversal activity.
Nitric oxide reverses drug resistance by inhibiting ATPase activity of p-glycoprotein in human multi-drug resistant cancer cells
2018, Biochimica et Biophysica Acta - General Subjects
Citation Excerpt :
While ADR is known to cause many biological/pharmacological effects in tumor cells, there are two main mechanisms that have been suggested to play important roles in tumor cell killing [37,40,43]. First, ADR induces both single- and double-strand breaks via acting as a topo II poison [27,41,42] and secondly, it generates reactive hydroxyl radicals following reductive activation at or near DNA, inducing DNA damage leading to tumor cell death [33–35,45]. We have examined both mechanisms in the presence of PPNO as an explanation for the reversal of ADR resistance.
Development of resistance to chemotherapy drugs is a significant problem in treating human malignancies in the clinic. Overexpression of drug efflux proteins, including P-170 glycoprotein (P-gp), an ATP-dependent efflux protein, is one of the main mechanisms responsible for multi-drug resistance (MDR). Because our previous studies have shown that nitric oxide (^˙NO) or its related species inhibit the ATPase activities of topoisomerase II, we hypothesized that ^˙NO should also inhibit the ATPase activity of P-gp and increase drug accumulation in MDR cells, causing a reversal of drug resistance.
Cytotoxicity and cellular accumulation studies showed that ^˙NO significantly inhibited the ATPase activity of P-gp in isolated membranes and in NCI/ADR-RES tumor cells, causing an increase in drug accumulation and reversals of adriamycin and taxol resistance in the MDR cells. While ^˙NO had no effects on topoisomerase II-induced, adriamycin-dependent DNA cleavage complex formation, it significantly inhibited adriamycin-induced DNA double-strand breaks. Electron spin resonance studies showed an increase in adriamycin-dependent hydroxyl radical formation in the presence of an NO-donor.
The reversal of drug resistance is due to inhibition of the ATPase activity by ^˙NO, resulting in enhancement of the drug accumulation in the MDR cells. Furthermore, DNA damage was not responsible for this reversal of adriamycin resistance. However, formation of adriamycin-dependent toxic free radical species and subsequent cellular damage may be responsible for the increased cytotoxicity of adriamycin by ^˙NO in NCI/ADR-RES cells.
Appropriately designed NO donors would be ideal for the treatment of P-gp-overexpressing tumors in the clinic.
ROS signalling in the biology of cancer
2018, Seminars in Cell and Developmental Biology
Citation Excerpt :
Daunorubicin, an anthracycline is used in the treatment of AML, acute lymphoblastic leukaemia (ALL) and acute promyelocytic leukaemia (APL). It reacts with cytochrome p450 reductase [242–244] in the presence of reduced NADPH to form semiquinone radical intermediates [245,246] that react with O2 to form O2− [245,247–251]. This leads to increased activation of neutral sphingomyelinase enzyme and increased ceramide resulting in activation of the JNK pathway leading to apoptosis [252,253].
Increased reactive oxygen species (ROS) production has been detected in various cancers and has been shown to have several roles, for example, they can activate pro-tumourigenic signalling, enhance cell survival and proliferation, and drive DNA damage and genetic instability. Counterintuitively ROS can also promote anti-tumourigenic signalling, initiating oxidative stress-induced tumour cell death. Tumour cells express elevated levels of antioxidant proteins to detoxify elevated ROS levels, establish a redox balance, while maintaining pro-tumourigenic signalling and resistance to apoptosis. Tumour cells have an altered redox balance to that of their normal counterparts and this identifies ROS manipulation as a potential target for cancer therapies. This review discusses the generation and sources of ROS within tumour cells, the regulation of ROS by antioxidant defence systems, as well as the effect of elevated ROS production on their signalling targets in cancer. It also provides an insight into how pro- and anti-tumourigenic ROS signalling pathways could be manipulated in the treatment of cancer.
Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells
2016, Biochimica et Biophysica Acta - General Subjects
Citation Excerpt :
The most interesting and somewhat surprising finding is that PPNO treatment had no significant effect on DOX-induced cleavable complex formation nor did it have any significant effects on DOX cytotoxicity in these cells lines. While the mechanisms of DOX-induced tumor cell killing are extremely complicated and various mechanisms have been reported [16,54–56], DOX is also considered to be a topo II poison. Under conditions where both the catalytic and relaxation activity of topo II were inhibited by PPNO, resulting in significant resistance to VP-16, no effect on DOX cytotoxicity was observed in either HT-29 or MCF-7 tumor cells.
Etoposide and doxorubicin, topoisomerase II poisons, are important drugs for the treatment of tumors in the clinic. Topoisomerases contain several free sulfhydryl groups which are important for their activity and are also potential targets for nitric oxide (NO)-induced nitrosation. NO, a physiological signaling molecule nitrosates many cellular proteins, causing altered protein and cellular functions.
Here, we have evaluated the roles of NO/NO-derived species in the activity/stability of topo II both in vitro and in human tumor cells, and in the cytotoxicity of topo II-poisons, etoposide and doxorubicin.
Treatment of purified topo IIα with propylamine propylamine nonoate (PPNO), an NO donor, resulted in inhibition of both the catalytic and relaxation activity in vitro, and decreased etoposide-dependent cleavable complex formation in both human HT-29 colon and MCF-7 breast cancer cells. PPNO treatment also induced significant nitrosation of topo IIα protein in these human tumor cells. These events, taken together, caused a significant resistance to etoposide in both cell lines. However, PPNO had no effect on doxorubicin-induced cleavable complex formation, or doxorubicin cytotoxicity in these cell lines.
Inhibition of topo II function by NO/NO-derived species induces significant resistance to etoposide, without affecting doxorubicin cytotoxicity in human tumor cells.
As tumors express inducible nitric oxide synthase and generate significant amounts of NO, modulation of topo II functions by NO/NO-derived species could render tumors resistant to certain topo II-poisons in the clinic.
Development of immunoblotting techniques for DNA radical detection
2013, Free Radical Biology and Medicine
Radical damage to DNA has been implicated in cell death, cellular dysfunction, and cancer. A recently developed method for detecting DNA radicals uses the nitrone spin trap DMPO (5,5-dimethyl-1-pyrroline N-oxide) to trap radicals. The trapped radicals then decay into stable nitrone adducts detectable with anti-DMPO antibodies and quantifiable by ELISA or dot-blot assay. However, the sequences of DNA that are damaged are likely to be as important as the total level of damage. Therefore, we have developed immunoblotting methods for detection of DNA nitrone adducts on electrophoretically separated DNA, comparable to Western blotting for proteins. These new techniques not only allow the assessment of relative radical adduct levels, but can reveal specific DNA fragments, and ultimately nucleotides, as radical targets. Moreover, we have determined that denaturation of samples into single-stranded DNA enhances the detection of DNA–DMPO adducts in our new blotting methods and also in ELISA.

View all citing articles on Scopus

View full text

Review articleFree radicals in anticancer drug pharmacology

Abstract

Biochim. Biophys. Acta

Biochim. Biophys. Acta

Biochem. Pharmacol.

Chem.-Biol. Interact.

Biochem. Pharmacol.

Biochem. Biophys. Res. Commun.

Biochem. Pharmacol.

Biochim. Biophys. Acta

Biochem. Pharmacol.

Biochem. Pharmacol.

Biochem. Pharmacol.

Biochim. Biophys. Acta

Biochem. Pharmacol.

Biochem. Biophys. Res. Commun.

Biochem. Pharmacol.

J. Biol. Chem.

Biochem. Pharmacol.

J. Free-Rad. Biol. Med.

FEBS Lett.

J. Biol. Chem.

J. Biol. Chem.

FEBS Lett.

J. Biol. Chem.

FEBS Lett.

Eur. J. Cancer

Biochim. Biophys. Acta

Biochem. Pharmacol.

Biochem. Biophys. Res. Commun.

Biochem. Pharmacol.

Biochem. Pharmacol.

Biochem. Pharmacol.

J. Biol. Chem.

Chem.-Biol. Interact.

FEBS Lett.

Life Sci.

Biochem. Pharmacol.

Free radical intermediates in the metabolism of toxic chemicals

Molecular mechanism of action of anticancer agents involving free radical intermediates

Adv. Free-Rad. Biol. Med.

A general mechanism for microsomal activation of quinone anticancer agents

Cancer Res.

Adriamycin-enhanced lipid peroxidation in isolated rat nuclei

Cancer Res.

Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics

Cancer Res.

Role of NADPH-cytochrome c reductase and DT-diaphorase in the bioactivation of mitomycin C

Cancer Res.

Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase

J. Biol. Chem.

Further studies on the generation of reactive oxygen species from activated anthracyclines and the relationship to cytotoxic action and cardiotoxic effects

Biochem. Pharmacol.

The mode of interactions of mitomycin C with deoxyribonucleic acids and other polynucleotides in vitro

Biochemistry

Formation of superoxide and hdyroxyl radicals in iron (II)-bleomycin-oxygen systems: electron spin resonance detection by spin trapping

J. Antiobiot. (Tokyo)

Effects of chelating agents and metal ions on the degradation of DNA by bleomycin

Biochemistry

An active intermediate formed in the reaction of bleomycin-Fe (II) complex with oxygen

J. Antibiot. (Tokyo)

Binding specificity of activated anthracycline anticancer agents to nucleic acids

Chem.-Biol. Interact.

Enzymatic activation and binding off Adriamycin to nuclear DNA

Cancer Res.

Review article
Free radicals in anticancer drug pharmacology